Equities analysts predict that Cardinal Health Inc (NYSE:CAH) will announce $33.59 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Cardinal Health’s earnings. The highest sales estimate is $33.91 billion and the lowest is $32.83 billion. Cardinal Health reported sales of $32.64 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 2.9%. The company is expected to report its next earnings results on Monday, November 5th.

On average, analysts expect that Cardinal Health will report full-year sales of $140.60 billion for the current financial year, with estimates ranging from $138.92 billion to $141.71 billion. For the next financial year, analysts anticipate that the company will report sales of $145.97 billion per share, with estimates ranging from $144.95 billion to $146.83 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Cardinal Health.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Monday, August 6th. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.93 by $0.08. The firm had revenue of $35.35 billion for the quarter, compared to analyst estimates of $34.38 billion. Cardinal Health had a net margin of 0.19% and a return on equity of 22.59%. Cardinal Health’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $1.31 EPS.

A number of research analysts recently weighed in on CAH shares. Mizuho reaffirmed a “hold” rating and issued a $53.00 price target on shares of Cardinal Health in a research note on Sunday, August 12th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $56.00 price target on shares of Cardinal Health in a research note on Tuesday, August 7th. Argus decreased their price target on shares of Cardinal Health from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, July 16th. Robert W. Baird reaffirmed a “hold” rating and issued a $51.00 price target on shares of Cardinal Health in a research note on Friday, July 20th. Finally, Morgan Stanley decreased their target price on shares of Cardinal Health from $55.00 to $40.00 and set an “underweight” rating on the stock in a research note on Tuesday, July 3rd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $62.31.

Cardinal Health stock traded down $0.02 during midday trading on Tuesday, reaching $55.15. The company had a trading volume of 60,948 shares, compared to its average volume of 2,734,275. The firm has a market capitalization of $16.66 billion, a PE ratio of 11.01, a P/E/G ratio of 1.68 and a beta of 1.04. Cardinal Health has a 12-month low of $48.14 and a 12-month high of $75.75. The company has a current ratio of 1.07, a quick ratio of 0.53 and a debt-to-equity ratio of 1.32.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 15th. Shareholders of record on Monday, October 1st will be paid a $0.4763 dividend. This represents a $1.91 dividend on an annualized basis and a yield of 3.45%. This is a positive change from Cardinal Health’s previous quarterly dividend of $0.48. The ex-dividend date of this dividend is Friday, September 28th. Cardinal Health’s dividend payout ratio (DPR) is 38.20%.

In other Cardinal Health news, CEO Jon L. Giacomin sold 2,890 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $51.95, for a total value of $150,135.50. Following the transaction, the chief executive officer now directly owns 72,652 shares of the company’s stock, valued at approximately $3,774,271.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.97% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Signaturefd LLC acquired a new stake in shares of Cardinal Health during the 1st quarter worth approximately $100,000. Optimum Investment Advisors acquired a new stake in shares of Cardinal Health during the 1st quarter worth approximately $128,000. Sentry Investment Management LLC acquired a new stake in shares of Cardinal Health during the 2nd quarter worth approximately $132,000. Mount Yale Investment Advisors LLC acquired a new stake in shares of Cardinal Health during the 1st quarter worth approximately $136,000. Finally, Exane Asset Management acquired a new stake in shares of Cardinal Health during the 2nd quarter worth approximately $153,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

Cardinal Health Company Profile

Cardinal Health, Inc operates as an integrated healthcare services and products company in the United States and internationally. It provides medical products and pharmaceuticals, and solutions that enhance supply chain efficiency for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices.

Further Reading: Intrinsic Value and Stock Selection

Get a free copy of the Zacks research report on Cardinal Health (CAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardinal Health (NYSE:CAH)

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.